Cargando…

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial

We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open‐label, two‐period, crossover trial. After individual titration and a steady‐s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heise, T., Bain, S. C., Bracken, R. M., Zijlstra, E., Nosek, L., Stender‐Petersen, K., Rabøl, R., Rowe, E., Haahr, H. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063138/ https://www.ncbi.nlm.nih.gov/pubmed/26450456 http://dx.doi.org/10.1111/dom.12588

Ejemplares similares

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
por: Heise, Tim, et al.
Publicado: (2017)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
por: Koehler, Gerd, et al.
Publicado: (2013)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
por: Nosek, Leszek, et al.
Publicado: (2014)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
por: Ratner, R E, et al.
Publicado: (2013)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2014)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
por: Sorli, Christopher, et al.
Publicado: (2013)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
por: Goldenberg, Ronald M., et al.
Publicado: (2021)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
por: Vora, J., et al.
Publicado: (2016)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
por: Vora, Jiten, et al.
Publicado: (2014)

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
por: Cheng, Alice, et al.
Publicado: (2019)

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study
por: Sullivan, Sean D., et al.
Publicado: (2019)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
por: Yamabe, Mizuho, et al.
Publicado: (2018)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
por: Evans, Marc, et al.
Publicado: (2020)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
por: Liu, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nfrpkuc5eio7rs0nli15c0e1li